In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein

Zheng, Juzeng; Lin, Xiuqing; Wang, Xiuyan; Zheng, Lei; Lan, Songsong; Jin, Sisi; Ou, Zhanfan; Wu, Jinming

doi:10.3390/v9050112

Cited by 59 publications

(43 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B-cell epitopes are two types, linear (continuous) and conformational (discontinuous). An online database of ABCPred was used to predict linear B-cell epitopes [38, 39]. Conformational epitopes were predicted by Ellipro server [40].…”

Section: Methodsmentioning

confidence: 99%

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Qamar¹,

Rehman

Ashfaq

et al. 2020

Preprint

View full text Add to dashboard Cite

1Coronavirus disease 2019 (COVID-19) associated pneumonia caused by severe acute respiratory 2 coronavirus 2 (SARS-COV-2) was first reported in Wuhan, China in December 2019. Till date, 3 no vaccine or completely effective drug is available for the cure of COVID-19. Therefore, an 4 effective vaccine against SARS-COV-2 is needed to be design. This study was conducted to 5 design an effective multi-epitope vaccine (MEV) against SARS-COV-2. Seven antigenic 6 proteins were taken as a target and epitopes (B cell, IFNγ and T cell) were predicted. Highly 7 antigenic and overlapping epitopes were shortlisted. Selected T cell epitopes indicated significant 8 interactions with the HLA-binding alleles and 99.29% coverage of the world's population. 9 Finally, 505 amino acids long MEV was designed by connecting sixteen MHC class I and twelve 1 0 MHC class II epitopes with suitable linkers and adjuvant. Linkers and adjuvant were added to 1 1 enhance the immunogenicity response of the vaccine. The allergenicity, physiochemical 1 2 properties, antigenicity and structural details of MEV were analyzed in order to ensure safety and 1 3 immunogenicity. MEV construct was non-allergenic and antigenic. Molecular docking 1 4 demonstrated a stable and strong binding affinity of MEV with TLR3 and TLR8. Codon 1 5 optimization and in silico cloning ensured increased expression in the Escherichia coli K-12 1 6system. However, to ensure its safety and immunogenic profile, the proposed vaccine needs to be 1 7 experimentally validated. 1 8

show abstract

Section: Methodsmentioning

confidence: 99%

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Qamar¹,

Rehman

Ashfaq

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…These vaccines are mainly made up of B-cell, CD 8þ cytolytic T-cell (CTLs) and CD 4þ helper T-cells (HTLs) epitopes (Chiarella et al, 2009). Since the antigenic epitopes of a protein could be predicted and detected, therefore the whole protein is not suitable to stimulate an immune response (Testa & Philip, 2012;Zheng et al, 2017). During the development of a vaccine candidate against COVID-19, complex pathogenic mechanisms and numerous pathogenic factors should be considered in vaccine formulation.…”

Section: Introductionmentioning

confidence: 99%

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

Enayatkhani

Hassaniazad

Faezi

et al. 2020

Journal of Biomolecular Structure and Dynamics

232

205

View full text Add to dashboard Cite

At present, novel Coronavirus (2019-nCoV, the causative agent of COVID-19) has caused worldwide social and economic disruption. The disturbing statistics of this infection promoted us to develop an effective vaccine candidate against the COVID-19. In this study, bioinformatics approaches were employed to design and introduce a novel multi-epitope vaccine against 2019-nCoV that can potentially trigger both CD 4þ and CD 8þ T-cell immune responses and investigated its biological activities by computational tools. Three known antigenic proteins (Nucleocapsid, ORF3a, and Membrane protein, hereafter called NOM) from the virus were selected and analyzed for prediction of the potential immunogenic B and T-cell epitopes and then validated using bioinformatics tools. Based on in silico analysis, we have constructed a multi-epitope vaccine candidate (NOM) with five rich-epitopes domain including highly scored T and B-cell epitopes. After predicting and evaluating of the third structure of the protein candidate, the best 3 D predicted model was applied for docking studies with Toll-like receptor 4 (TLR4) and HLA-A Ã 11:01. In the next step, molecular dynamics (MD) simulation was used to evaluate the stability of the designed fusion protein with TLR4 and HLA-A Ã 11:01 receptors. MD studies demonstrated that the NOM-TLR4 and NOM-HLA-A Ã 11:01 docked models were stable during simulation time. In silico evaluation showed that the designed chimeric protein could simultaneously elicit humoral and cell-mediated immune responses.

show abstract

“…Thus, they have been broadly applied for a range of viral, bacterial, and parasitic diseases [24][25][26]. The most important factors for designing a multi-epitope vaccine are predicting and screening the functional neutralizing B cell epitopes and species-restricted T cell epitopes [27,28]. IBV spike glycoprotein (S) is proteolytically cleaved into a 92-kDa S1 subunit and a 84-kDa S2 subunit, and these play an important role in viral infections [29].…”

Section: Introductionmentioning

confidence: 99%

A Recombinant La Sota Vaccine Strain Expressing Multiple Epitopes of Infectious Bronchitis Virus (IBV) Protects Specific Pathogen-Free (SPF) Chickens against IBV and NDV Challenges

et al. 2019

View full text Add to dashboard Cite

Infectious bronchitis (IB) and Newcastle disease (ND) are two major infectious diseases that are a threat to the domestic poultry industry. In this study, we successfully generated a recombinant LaSota candidate vaccine strain, rNDV-IBV-T/B, which expresses a short, synthetic, previously identified IBV S1 multi-epitope cassette using the reverse genetic system. The recombinant virus was propagated in nine-day-old embryonated chicken eggs for 20 passages and genetic stability was confirmed by whole genome DNA sequencing. The recombinant virus had a hemagglutination (HA) titer of 2 10 , mean death time (MDT) of 118 hours, and intracerebral pathogenicity index (ICPI) of 0.05. None of these were significantly different from the parental Newcastle disease virus (NDV) LaSota strain (p > 0.05). Vaccination of white leghorn chickens at one day of age with 10 6 EID 50 rNDV-IBV-T/B provided 90% protection against virulent IBV M41 challenge at three weeks of age, which was significantly higher than the protection of the control group vaccinated with phosphate-buffered saline (PBS) (p < 0.05). The ciliostasis scores of rNDV-IBV-T/B-vaccinated and LaSota-vaccinated groups were 4.2 and 37.6, respectively, which indicated that rNDV-IBV-T/B vaccination reduced the pathogenicity of IBV toward the trachea. Furthermore, real-time RT-PCR assay showed that the rNDV-IBV-T/B vaccination resulted in low levels of viral load (647.80 ± 49.65 RNA copies) in the trachea four days post-challenge, which is significantly lower than groups vaccinated with PBS (8591.25 ± 311.10 RNA copies) or LaSota (7742.60 ± 298.50 RNA copies) (p < 0.05). Meanwhile, the same dose of rNDV-IBV-T/B vaccination provided complete protection against velogenic NDV F48E9 challenge. These results demonstrate that the rNDV-IBV-T/B strain is a promising vaccine candidate to control both IB and ND simultaneously. Furthermore, epitope-based live vector vaccines provide an alternative strategy for the development of cost-effective and, broadly, cross-protective vaccines.

show abstract

In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein

Cited by 59 publications

References 79 publications

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics andin silicoapproaches

Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

A Recombinant La Sota Vaccine Strain Expressing Multiple Epitopes of Infectious Bronchitis Virus (IBV) Protects Specific Pathogen-Free (SPF) Chickens against IBV and NDV Challenges

Contact Info

Product

Resources

About